Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312101 | 0.88 | HTR2C (0.47) | HTR2CCTSLCTSBCTSKMAPT | |
| SCHEMBL30751773 | 0.86 | CYP3A4 (0.55) | HTR2CPNMTCD44MAOBCTSL | |
| SCHEMBL2401358 | 0.86 | CYP3A4 (0.55) | HTR2CPNMTCD44MAOBCTSL | |
| SCHEMBL5550904 | 0.84 | ALDH1A1 (0.46) | HTR2CCTSLCTSBCTSKMAPT | |
| SCHEMBL6307293 | 0.80 | MEN1 (0.43) | HTR2CCTSLCTSBCTSKMAPT | |
| SCHEMBL11833898 | 0.80 | CYP3A4 (0.46) | HTR2CPNMTCD44MAOBCTSL | |
| Acridine SCHEMBL4792433 | 0.79 | PNMT (0.66) | HTR2CPNMTCD44MAOBMAPT | |
| SCHEMBL6312545 | 0.79 | ALDH1A1 (0.47) | PNMTCD44MAOBMAPTALDH1A1 | |
| SCHEMBL28981243 | 0.77 | ALDH1A1 (0.52) | CTSLCTSBCTSKMAPTALDH1A1 | |
| SCHEMBL7929258 | 0.77 | ALDH1A1 (0.46) | CTSLCTSBCTSKMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-06-29 | — | — | US | disclosed |
| WO-2023112038-A1 | NEUTROPHIL EXOCYTOSIS INHIBITORS | IMMUNYX PHARMA LTD. (IL) | 2023-06-22 | — | — | WO | disclosed |
| US-20230124527-A1 | NANOPARTICLES FOR CHEMIRESISTOR SENSORS | NANOSCENT LTD. (IL) | 2023-04-20 | — | — | US | disclosed |
| US-20230104413-A1 | NANOPARTICLES FOR CHEMIRESISTOR SENSORS | NANOSCENT LTD. (IL) | 2023-04-06 | — | — | US | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| EP-4004127-A1 | COATING COMPOSITIONS WITH POLYSILOXANE-MODIFIED CARBON NANOPARTICLE | Valfre' di Bonzo, Roberto (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-11307158-B1 | Nanoparticles for chemiresistor sensors | NANOSCENT LTD. (IL) | 2022-04-19 | — | — | US | disclosed |
| US-20130184206-A1 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2222636-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARM INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8354446-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2489656-A1 | Selective androgen receptor modulators (sarms) and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120064022-A1 | CYCLOSILOXANE-SUBSTITUTED POLYSILOXANE COMPOUNDS, COMPOSITIONS CONTAINING THE COMPOUNDS AND METHODS OF USE THEREOF | BIOFILM, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2012-01-05 | — | — | US | disclosed |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED | 2010-10-07 | — | — | US | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | APOL1, APOB, LIPA | HTR2C 4623/4885PNMT 3826/4885CD44 3557/4885 |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | HTR2C 4752/4885PNMT 890/4885CD44 88/4885 |
| US-20130184206-A1 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | HTR2C 753/4885PNMT 1492/4885CD44 3548/4885 |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | HTR2C 107/4885PNMT 463/4885CD44 4078/4885 |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | HTR2C 661/4885PNMT 1663/4885CD44 3529/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | HTR2C 4528/4885PNMT 4517/4885CD44 26/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | HTR2C 755/4885PNMT 1602/4885CD44 3966/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | HTR2C 4559/4885PNMT 3078/4885CD44 3633/4885 |
| US-20120064022-A1 | CYCLOSILOXANE-SUBSTITUTED POLYSILOXANE COMPOUNDS, COMPOSITIONS CONTAINING THE COMPOUNDS AND METHODS OF USE THEREOF | PIEZO1, DSC1, PFAS | HTR2C 2160/4885PNMT 3700/4885CD44 906/4885 |
| US-20120004220-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | HTR2C 661/4885PNMT 1663/4885CD44 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.